OpenAI announced the public availability of GPT‑Rosalind, a frontier reasoning model tailored for life sciences research. The model, which has moved out of research preview, is now accessible to eligible organizations through a trusted‑access program and is integrated into ChatGPT, Codex, and the API. OpenAI highlights that GPT‑Rosalind is optimized for scientific workflows, combining improved tool use with deeper understanding across chemistry, protein engineering, and genomics. In benchmark evaluations, the model achieved leading performance on BixBench and outperformed GPT‑5.4 on 6 of 11 tasks in LABBench2, notably excelling in CloningQA. A partnership with Dyno Therapeutics demonstrated that best‑of‑ten model submissions ranked above the 95th percentile of human experts on an RNA sequence‑to‑function prediction task and around the 84th percentile on a sequence generation task. OpenAI also released a freely accessible Life Sciences research plugin for Codex, available on GitHub, which provides modular skills for common research workflows and access to more than 50 public multi‑omics databases, literature sources, and biology tools. The plugin is intended to help scientists navigate complex, multi‑step questions and is available to all users, while eligible enterprise users can combine it with GPT‑Rosalind for deeper biological reasoning. OpenAI emphasizes that the model is named after Rosalind Franklin and that it represents the first release in a series that will expand biochemical reasoning capabilities across long‑horizon, tool‑heavy scientific workflows. The company stresses that the launch will maintain strong safeguards against biological misuse and will initially target qualified U.S. enterprise customers with controls around eligibility, access management, and governance. The broader availability of connectors and the plugin aims to enable researchers to use OpenAI’s mainline models more effectively for life‑sciences applications.
Introducing GPT-Rosalind for life sciences research
OpenAI has released GPT‑Rosalind, a specialized reasoning model for life sciences, now available globally to eligible organizations through a trusted‑access program. The model is designed to accelerate drug discovery, genomics analysis, protein reasoning, and other scientific workflows, and is integrated into ChatGPT, Codex, and the API. A free Life Sciences research plugin for Codex, providing access to over 50 scientific tools and databases, is also available. OpenAI claims GPT‑Rosalind outperforms existing models on benchmarks such as BixBench and LABBench2 and has shown strong results in real‑world evaluations with Dyno Therapeutics.
Why it matters
The introduction of a domain‑specific AI model that demonstrates measurable gains in scientific reasoning could accelerate drug discovery timelines and set a precedent for specialized AI deployments in regulated industries.